Abstract
Angiomotin (AMOT) is a membrane protein that is aberrantly expressed in a variety of solid tumors. Accumulating evidence support that AMOT is involved in the pathological processes of tumor proliferation, apoptosis, and invasion. However, the potential role of AMOT in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) remains elusive. In the present study, we investigated the expression level and biological function of AMOT in DLBCL. AMOT expression was significantly reduced in DLBCL biopsy section, and low AMOT expression was associated with poor clinical prognosis. Overexpression of AMOT by lentivirus in human DLBCL cells induced cell viability inhibition concomitant with an increased percentage of cells in G1 phase and decreased percentage in S phase. Moreover, AMOT upregulation increased the sensitivity of DLBCL cells to doxorubicin. Furthermore, overexpression of AMOT led to reduced activation of key kinases for the DNA damage response (DDR). The above results indicated that AMOT acts as a tumor suppressor via inhibition of the DDR, thus reducing the viability while increasing the chemosensitivity in DLBCL. In summary, AMOT may be a novel potential target for DLBCL therapeutic intervention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Availability of data and materials
All data generated and analyzed during this study are included in this article and its supplementary information files.
References
Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;1:12–23.
Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pr Res Clin Haematol. 2018;3:209–16.
Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019;4:253–65.
Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015;1:22–32.
Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001;6:1247–54.
Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, et al. Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 2002;1:69–77.
Bratt A, Birot O, Sinha I, Veitonmaki N, Aase K, Ernkvist M, et al. Angiomotin regulates endothelial cell-cell junctions and cell motility. J Biol Chem. 2005;41:34859–69.
Ernkvist M, Aase K, Ukomadu C, Wohlschlegel J, Blackman R, Veitonmaki N, et al. p130-angiomotin associates to actin and controls endothelial cell shape. FEBS J. 2006;9:2000–11.
Ernkvist M, Birot O, Sinha I, Veitonmaki N, Nystrom S, Aase K, et al. Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells. Biochim Biophys Acta. 2008;3:429–37.
Ortiz A, Lee YC, Yu G, Liu HC, Lin SC, Bilen MA, et al. Angiomotin is a novel component of cadherin-11/beta-catenin/p120 complex and is critical for cadherin-11-mediated cell migration. FASEB J. 2015;3:1080–91.
Shimono A, Behringer RR. Angiomotin regulates visceral endoderm movements during mouse embryogenesis. Curr Biol. 2003;7:613–7.
Ranahan WP, Han Z, Smith-Kinnaman W, Nabinger SC, Heller B, Herbert BS, et al. The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases. Cancer Res. 2011;6:2203–11.
Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell. 2011;4:527–40.
Aase K, Ernkvist M, Ebarasi L, Jakobsson L, Majumdar A, Yi C, et al. Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev. 2007;16:2055–68.
Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, et al. YAP1-mediated suppression of USP31 enhances NFkappaB activity to promote sarcomagenesis. Cancer Res. 2018;10:2705–20.
Wang Y, Justilien V, Brennan KI, Jamieson L, Murray NR, Fields AP. PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene 2017;4:534–45.
Chen ZL, Yang J, Shen YW, Li ST, Wang X, Lv M, et al. AmotP130 regulates Rho GTPase and decreases breast cancer cell mobility. J Cell Mol Med. 2018;4:2390–403.
Hsu YL, Hung JY, Chou SH, Huang MS, Tsai MJ, Lin YS, et al. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Oncogene 2015;31:4056–68.
Yang J, Liu P, Tian M, Li Y, Chen W, Li X. Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma. Int J Oncol. 2013;6:2078–86.
Lin X, Spindler TJ, Fonseca MA, Corona RI, Seo JH, Dezem FS, et al. Super-enhancer-associated LncRNA UCA1 interacts directly with AMOT to activate YAP target genes in epithelial ovarian cancer. iScience. 2019;17:242–55.
Liu Y, Lu Z, Shi Y, Sun F. AMOT is required for YAP function in high glucose induced liver malignancy. Biochem Biophys Res Commun. 2018;1:1555–61.
Ruan WD, Wang P, Feng S, Xue Y, Zhang B. MicroRNA-497 inhibits cell proliferation, migration, and invasion by targeting AMOT in human osteosarcoma cells. Onco Targets Ther. 2016;9:303–13.
Byun JY, Lee SH, Shin JM, Baek BJ, Lee JY. Overexpression of angiomotin in sinonasal inverted papilloma. Int Forum Allergy Rhinol. 2014;6:512–6.
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011;1:51–63.
Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci USA. 2013;43:17368–73.
Chan SW, Lim CJ, Guo F, Tan I, Leung T, Hong W. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. J Biol Chem. 2013;52:37296–307.
Mana-Capelli S, McCollum D. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling. J Biol Chem. 2018;47:18230–41.
Yang J, Zhang X, Chen Z, Shen Y, Wang F, Wang Y, et al. Angiomotin-p130 inhibits beta-catenin stability by competing with Axin for binding to tankyrase in breast cancer. Cell Death Dis. 2019;3:179.
Zhang H, Sun J, Ju W, Li B, Lou Y, Zhang G, et al. Apatinib suppresses breast cancer cells proliferation and invasion via angiomotin inhibition. Am J Transl Res. 2019;7:4460–9.
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–5.
Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Bakalarski CE, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6.
Kraft D, Rall M, Volcic M, Metzler E, Groo A, Stahl A, et al. NF-kappaB-dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells. Leukemia 2015;7:1543–54.
Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;9:1–17.
Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13:77.
Yang J, Li Y, Zhang Y, Fang X, Chen N, Zhou X, et al. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. J Exp Clin Cancer Res. 2020;39:142.
Huang T, Zhou Y, Zhang J, Cheng ASL, Yu J, To KF, et al. The physiological role of Motin family and its dysregulation in tumorigenesis. J Transl Med. 2018;1:98.
Hong SA, Son MW, Cho J, Jang SH, Lee HJ, Lee JH, et al. Low angiomotin-p130 with concomitant high Yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer. APMIS 2017;11:996–1006.
Vinci G, Buffat C, Simoncini S, Boubred F, Ligi I, Dumont F, et al. Gestational age-related patterns of AMOT methylation are revealed in preterm infant endothelial progenitors. PLoS ONE. 2017;10:e0186321.
Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Disco. 2012;12:923–36.
Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T, et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011;6:1340–54.
Wang H, Lu B, Castillo J, Zhang Y, Yang Z, McAllister G, et al. Tankyrase inhibitor sensitizes lung cancer cells to endothelial growth factor receptor (EGFR) inhibition via stabilizing angiomotins and inhibiting YAP signaling. J Biol Chem. 2016;29:15256–66.
Wang W, Li N, Li X, Tran MK, Han X, Chen J. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 2015;3:524–32.
Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73–112.
Viziteu E, Kassambara A, Pasero P, Klein B, Moreaux J. RECQ helicases are deregulated in hematological malignancies in association with a prognostic value. Biomark Res. 2016;4:3.
Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;5:739–45.
Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics[J]. Trends Mol Med. 2011;2:88–96.
Ge C, Vilfranc CL, Che L, Pandita RK, Hambarde S, Andreassen PR, et al. The BRUCE-ATR signaling axis is required for accurate DNA replication and suppression of liver cancer development. Hepatology 2019;6:2608–22.
Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019;104:2443–55.
Yuan J, Adamski R, Chen J. Focus on histone variant H2AX: to be or not to be. FEBS Lett. 2010;17:3717–24.
Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem. 2011;7:2320–30.
Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7:428–30.
Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA, et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer. 2012;2:291–9.
Funding
This study was funded by Translational Research Grant of National Clinical Research Center for Hematologic Diseases (NCRCH) (No. 2020ZKMB01); National Natural Science Foundation (No. 81800194, No. 82070203, No. 81770210, No. 81270598, and No. 81473486); Key Research and Development Program of Shandong Province (No. 2018CXGC1213); Technology Development Projects of Shandong Province (No. 2017GSF18189); Shandong Provincial Natural Science Foundation (No. ZR2018BH011); China Postdoctoral Science Foundation (No. 2020M672103); Development Project of Youth Innovation Teams in Colleges and Universities of Shandong Province (No. 2020KJL006); Technology Development Project of Jinan City (No. 201805065); Taishan Scholars Program of Shandong Province; Academic promotion programme of Shandong First Medical University; Shandong Provincial Engineering Research Center of Lymphoma.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sang, T., Yang, J., Liu, J. et al. AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma. Cancer Gene Ther 28, 1125–1135 (2021). https://doi.org/10.1038/s41417-020-00258-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41417-020-00258-5
This article is cited by
-
The role of Motin family proteins in tumorigenesis—an update
Oncogene (2023)
-
Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma
Cell Death & Disease (2021)